James Purzner
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
BACKGROUND Glioblastoma (GB) typically recurs locally and maintains a glial histopathological phenotype. Sarcomatoid transformation is rare, and distal extra-axial recurrence with bone and soft tissue involvement is exceptionally uncommon. Molecular features of such sarcomatoid transformations remain poorly described. OBSERVATIONS The authors present the case of a 53-year-old man with a history of right temporal GB ( IDH -wildtype, MGMT -unmethylated) treated with maximal safe resection and chemoradiotherapy. Eleven months postoperatively, surveillance MRI demonstrated local enhancement with a new left parasagittal extra-axial lesion with bony and subgaleal extension. Debulking and resection revealed a high-grade sarcomatoid tumor with focal glial immunophenotype, mimicking a secondary gliosarcoma but with near-complete predominance of the sarcomatous component. Molecular analysis demonstrated preservation of TERT , PIK3CA , and PTEN variants identified in the original GB, with acquisition of a TP53 mutation. LESSONS This case illustrates a rare pattern of GB progression, characterized by distal extra-axial recurrence with sarcomatoid transformation. The shared driver TERT , PIK3CA , and PTEN mutations in the original right temporal and subsequent left extra-axial lesion support clonal evolution, while the newly acquired TP53 alteration may underlie histological shift. Clinicians should consider histological transformation when evaluating atypical or extracranial recurrences, as molecular continuity with the primary tumor can guide interpretation of tumor biology and recurrence patterns. https://thejns.org/doi/10.3171/CASE25714
Year:
2026
Year:
2026
BACKGROUND AND OBJECTIVES: The ability to molecularly characterize spatially heterogeneous tumors, such as primary brain tumors, depends on the efficient and consistent collection of spatially defined tissue samples free of cross-contamination. Currently available neurosurgical tools, designed for clinical use rather than modern molecular characterization, limit our view of heterogeneous processes to snapshots of single regions. This study introduces a novel biopsy device that enables the precise, reproducible, and spatially registered collection of tissue across a tumor and surgical cavity, paving the way for advancements in personalized tumor characterization and treatment. METHODS: Prototypes were developed using a Quality Function Deployment framework to prioritize user requirements and technical needs. Iterative modeling and 3D printing produced prototypes that underwent proof-of-concept and phantom testing. Final validation involved comparative testing of the novel biopsy tool and Yasargil tumor-grasping forceps by 6 neurosurgeons and 6 students. Clinical feasibility was assessed through the collection of 10 intraoperative tissue samples using each device. RESULTS: The lead design, which met all Quality Function Deployment requirements, consists of an optically tracked capsule that attaches to a Frazier suction. When suction is applied, a piston is pulled up and the sample is securely contained. After releasing the suction, manual depression ejects the tissue. In comparative testing, the capsule method reduced variability in sample weight and collection time compared with the Yasargil forceps. It also demonstrated greater ease of use, enabling students to achieve results comparable with experienced surgeons. Clinical testing revealed no differences in sample variability, tissue preservation, or instrument failure. CONCLUSION: This optically tracked navigated biopsy tool offers a low-cost, efficient, easily used, and consistent method for brain biopsy collection. The novel device is well suited for precision medicine and translational research needs.
Year:
2025
Medulloblastoma (MB), the most common malignant pediatric brain tumor, remains difficult to cure upon relapse, with only 12.4% of patients surviving five years post-recurrence. While specific quiescent tumor cell populations are known to contribute to treatment-resistance, the molecular mechanisms that maintain quiescence remain poorly defined. Here, we identify the cell cycle inhibitor p57 as a regulator of quiescence and chemotherapy resistance in Sonic Hedgehog (SHH) MB. Nuclear p57 was enriched in Sox2+ and Nestin+ stem-like MB cells compared to proliferative Atoh1+ cells. Inducing p57 expression in SHH MB cells led to a six-fold increase in G 0 -phase cells and conferred resistance to the frontline chemotherapeutic vincristine. Clinically, dexamethasone is a glucocorticoid given to nearly all MB patients to manage cerebral edema and is administered with wide variability in timing and dosing. We show that dexamethasone significantly increased nuclear p57 levels and expanded the G 0 population in both Ptch1 +/− and Ptch1 +/− ; Trp53 −/− SHH MB mouse models. Pre-treatment with dexamethasone reduced vincristine sensitivity in SHH MB cells. Together, our findings reveal a clinically relevant and previously unrecognized mechanism of treatment resistance, whereby dexamethasone, despite its benefits in managing edema, may inadvertently contribute to tumor persistence or recurrence by driving a quiescent, drug-resistant state. Addressing the lack of standardization in steroid use or targeting p57 may improve treatment response and reduce recurrence in patients diagnosed with SHH MB.
Year:
2025
Medulloblastoma (MB) is the most common malignant brain tumour in children. The Sonic Hedgehog (SHH)-medulloblastoma subtype arises from the cerebellar granule neuron lineage. Terminally differentiated neurons are incapable of undergoing further cell division, so an effective treatment for this tumour could be to force neuronal differentiation. Differentiation therapy provides a potential alternative for patients with medulloblastoma who harbor mutations that impair cell death pathways (TP53), which is associated a with high mortality. To this end, our goal was to explore epigenetic regulation of cerebellar granule neuron differentiation in medulloblastoma cells. Key regulators were discovered using chromatin immunoprecipitation with high-throughput sequencing. DNA-bound protein and chromatin protein modifications were investigated across all genes. We discovered that Ezh2-mediated tri-methylation of the H3 histone (H3K27me3), occurred on more than half of the 787 genes whose transcription normally increases as granule neurons terminally differentiate. Conditional knockout of Ezh2 led to early initiation of differentiation in granule neuron precursors (GNPs), but only after cell cycle exit had occurred. Similarly, in MB cells, neuronal differentiation could be induced by preventing H3K27me3 modifications using an Ezh2 inhibitor (UNC1999), but only when UNC1999 was combined with forced cell cycle exit driven by a CDK4/6 inhibitor (Palbociclib). Ezh2 emerges as a powerful restraint upon post-mitotic differentiation during normal GNP development and combination of Ezh2 inhibition with cell cycle exit leads to MB cell differentiation.
Year:
2025
Medulloblastoma (MB) is the most common malignant brain tumour in children. The Sonic Hedgehog (SHH)-medulloblastoma subtype arises from the cerebellar granule neuron lineage. Terminally differentiated neurons are incapable of undergoing further cell division, so an effective treatment for this tumour could be to force neuronal differentiation. Differentiation therapy provides a potential alternative for patients with medulloblastoma who harbor mutations that impair cell death pathways (TP53), which is associated a with high mortality. To this end, our goal was to explore epigenetic regulation of cerebellar granule neuron differentiation in medulloblastoma cells. Key regulators were discovered using chromatin immunoprecipitation with high-throughput sequencing. DNA-bound protein and chromatin protein modifications were investigated across all genes. We discovered that Ezh2-mediated tri-methylation of the H3 histone (H3K27me3), occurred on more than half of the 787 genes whose transcription normally increases as granule neurons terminally differentiate. Conditional knockout of Ezh2 led to early initiation of differentiation in granule neuron precursors (GNPs), but only after cell cycle exit had occurred. Similarly, in MB cells, neuronal differentiation could be induced by preventing H3K27me3 modifications using an Ezh2 inhibitor (UNC1999), but only when UNC1999 was combined with forced cell cycle exit driven by a CDK4/6 inhibitor (Palbociclib). Ezh2 emerges as a powerful restraint upon post-mitotic differentiation during normal GNP development and combination of Ezh2 inhibition with cell cycle exit leads to MB cell differentiation.
Year:
2024
Collaborators (3)
heidi-lynn ploeg
Professor
Queen's University
Michael Taylor
Professor
Baylor College of Medicine
Margaret T Fuller
Professor
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.